CA @L2017C_ONC

🫁 Catching up on #WCLC26 news? 🌟 Don't miss this insightful Q&A with Dr. Chad Rusthoven on the SWOG S1827/MAVERICK trial data he presented at the @IASLC Presidential Symposium! ➡️ Learn more: buff.ly/6MtXd8Z #lcsm #SCLC #WCLC2026

Updates in 9/2026 NCCN NSCLC Guidelines: sevabertinib as 1L option for HER2 mt NSCLC & daraxonrasib (off label at 200mg daily dosing) added to consider in pts with KRAS mutant NSCLC. In phase I/II, post chemo-IO, RR ~ 42%, DOR ~1y. Worth pursuing if no access to clinical trials.

Claude Codeでついに AGENTS.md をサポート！！ 長らくされていた議論に終止符が打たれる！

Thariq @trq212

7 days ago

We're adding support for AGENTS.md to Claude Code. Starting today in version 2.1.277, if there is no CLAUDE.md in a folder, Claude will check for and use AGENTS.md. You can toggle this behavior in /config.

2K 3K 31K 5.5M 6K

🔥Germline EGFR T790M mutation & lung cancer risk — 3.3 million person study 🆙 @ScienceMagazine Science 🎯OR 25.18 (p=1.9×10⁻²⁴) for lung cancer 🎯No association with 17 other cancers 🎯Never-smokers: 60-fold increased risk 🎯Southern Appalachian founder effect ~200 years ago; carrier freq 1 in 2,078 in that region 💡Findings support genetic testing & screening strategies for EGFR T790M carriers 🎙Dr. Jaclyn LoPiccolo Dr. Pasi A. Jänne @DanaFarberNews #LCSM @OncoAlert @Larvol @EGFRResisters science.org/doi/10.1126/sc…

🚨 A must-read update from ASTCT on immune effector cell toxicities 🔗 astctjournal.org/article/S2666-… 🔑 Key updates:
🔹 CRS/ICANS grading largely retained with important refinements
🔹 Modified ICE (M-ICE) introduced
🔹 ICAHT & IEC-HS updated
🔹 Non-ICANS neurotoxicities formally recognized—including TIAN 🧠
🔹 Enterocolitis, LICATS & on-target/off-tumor toxicities incorporated. Most importantly for solid tumors: this framework is explicitly intended to apply to T-cell engagers, not only CAR-T 🎯

Masahiro TORASAWA, MD. PhD. @M_Torasawa

6 months ago

🤔Is it really ICANS? Rethinking tarlatamab neurotoxicity 🚨Our case report has just been published in JTO (@JTOonline). jto.org/article/S1556-… 🧠 Severe neurotoxicity after tarlatamab in SCLC pt with brain mets can represent tumor inflammation-associated neurotoxicity

3 34 101 34K 46

🔥Genomic & transcriptomic features of relapsed SCLC 🆙 @JTOonline 🎯MYC/MYCL/MYCN amplifications; immune evasion via CD24 amp, IDO1 overexpression & HLA-E upregulation; splicing aberrations in relapse 🎙Dr. Siddhartha Devarakonda & Dr. Ramaswamy Govindan #LCSM @OncoAlert @Larvol jto.org/article/S1556-…

Can STK11 or KEAP1 co-mutations help us choose POSEIDON or CheckMate 9LA? The biology is compelling—but the evidence is still evolving. 🔹 STK11 → Immune-cold tumors with poor response to PD-(L)1 monotherapy. Adding CTLA-4 blockade (tremelimumab/ipilimumab) may partially overcome resistance. 🔹 KEAP1 → Aggressive biology and poor prognosis. Dual checkpoint blockade may improve outcomes, but it does not eliminate the adverse impact. 🔹 TP53 → Often immune-hot, with higher TMB/PD-L1 and generally better responses to immunotherapy. 📌 Key takeaway: STK11 and KEAP1 are established negative prognostic biomarkers. Exploratory analyses from POSEIDON and CheckMate 9LA suggest dual checkpoint blockade may be beneficial—particularly in STK11-mutant NSCLC—but these findings remain hypothesis-generating. Current NCCN/ESMO/ASCO guidelines do not recommend selecting these regimens solely based on co-mutation status. 🧬 Biology informs our decisions, but evidence should guide our practice. #LungCancer #NSCLC #ThoracicOncology #Immunotherapy #STK11 #KEAP1 #TP53 #POSEIDON #CheckMate9LA #CTLA4 #PDL1 #PrecisionOncology #CancerResearch #MedicalOncology #CancerConceptsExplained #OncologyEducation

#WCLC26 | ADAURA 8-year OS update 📚 JTO full text: jto.org/article/S1556-… 🧬 Exploratory long-term follow-up of adjuvant osimertinib ×3 years after complete resection of EGFR-mutated stage IB–IIIA NSCLC (n=682) 🏆 Stage IB–IIIA: • 8-y OS: 79% vs 64% • HR 0.52 (95% CI 0.39–0.71) → 15% absolute OS gain 📊 Stage II–IIIA: • 8-y OS: 74% vs 58% • HR 0.53 (95% CI 0.38–0.75) → 16% absolute gain 🔎 Benefit remained consistent by stage: • IB: 91% vs 77% | HR 0.50 • II: 78% vs 63% | HR 0.60 • IIIA: 70% vs 52% | HR 0.49 ⏳ Longest OS follow-up reported from a global adjuvant Ph3 trial in EGFR-mutated early-stage NSCLC

keyboard_arrow_left Previous keyboard_arrow_right Next

Landmark, practice changing study at #WCLC26. The phase III MAVERICK study shows no improvement in OS with PCI for SCLC, across limited and extensive stages, with worse cognitive failure free survival and increased toxicity in PCI arm. The end of the PCI era.

🆙#WCLC26 #LCSM Oral Session 🔥DeLLphi-309: Tarlatamab Extended-Interval Dosing Regimens in Patients With SCLC: The Randomized Phase 2 Study 🎙️Dr. Jonathan W. Goldman 🎯Tarlatamab extended-interval dosing may offer flexibility 🔢OA05.01 ☑️NCT06745323 🔗 cattendee.abstractsonline.com/meeting/21487/… @OncoAlert @Larvol @IASLC

keyboard_arrow_left Previous keyboard_arrow_right Next

Hidehito HORINOUCHI @HHorinouchi

a month ago

🆙#WCLC26 #LCSM Oral Session 🔥DeLLphi-309: Tarlatamab Extended-Interval Dosing Regimens in Patients With SCLC: The Randomized Phase 2 Study 🎙️Dr. Jonathan W. Goldman 🔢OA05.01 ☑️NCT06745323 🔗 cattendee.abstractsonline.com/meeting/21487/… @OncoAlert @Larvol @IASLC

0 8 16 8K 6

x.com/i/article/2099…

📝これはAIで文章を書く人なら必読の有益記事 私も最近Gemini 3.8 Flashを好んで使っているから学びが深いです！特にAIっぽさの原因を「文章を書く前の設計」に置いていること。当たり前だけど土台（計画）がとても重要。何度も読み込みたい記事に感謝ですっ　↓

こぎそ @kgsi

2 weeks ago

x.com/i/article/2098…

2 51 690 249K 2K

Dr. @MartinReck2 presents MDT-Bridge at #WCLC26: pts with resectable or borderline resectable NSCLC received 1-2 cycles of durvalumab + chemotherapy then surgery if resectable or CRT if not, followed by adjuvant/consolidation durvalumab. Of those with borderline resectable NSCLC, 62% underwent resection (97% R0). Overall resection rate 75% and 27% pCR rate.

keyboard_arrow_left Previous keyboard_arrow_right Next

🆙#WCLC26 #LCSM Oral Session 🔥MDT-BRIDGE: Neoadjuvant Durvalumab + Chemotherapy for Resectable/Borderline Resectable Stage IIB-IIIB NSCLC 🎙️ @MartinReck2 🔢OA04.02 🎯Resection Rate 74.6%; pCR 27.3% and 12-Mo EFS 90.1% in Resectable Cohort ☑️NCT05925530 🔗 cattendee.abstractsonline.com/meeting/21487/… @OncoAlert @Larvol @IASLC

keyboard_arrow_left Previous keyboard_arrow_right Next

Hidehito HORINOUCHI @HHorinouchi

a month ago

🆙#WCLC26 #LCSM Oral Session 🔥MDT-BRIDGE: Neoadjuvant Durvalumab + Chemotherapy for Resectable/Borderline Resectable Stage IIB-IIIB NSCLC 🎙️ @MartinReck2 🔢OA04.02 🎯Resection Rate 74.6%; pCR 27.3% and 12-Mo EFS 90.1% in Resectable Cohort ☑️NCT05925530 🔗

1 17 44 9K 20

PAPILLON: final OS Chemo+Ami 1L EGFR Ex20 Ins ❗️76% X-over ✅mOS 34 v 27m, HR 0.87 ✅X-over adjusted OS HR 0.57 🤔 Active, perhaps best OS data of 3 options (sunvo, zipa, ami) so far Adjusted OS data exploratory IMO Ami = challenging skin AEs #WCLC26

keyboard_arrow_left Previous keyboard_arrow_right Next

Final OS for 🦋 1L amivantamab +chemo for #EGFR exon20ins NSCLC showed OS benefit of 0.57, p=0.003 upon adjusting for crossover. @chulkimMD @IASLC #WCLC26 @EGFRResisters

keyboard_arrow_left Previous keyboard_arrow_right Next

Featured during #WCLC26 🚨: ADAURA, a global phase III adjuvant trial in EGFR-mutated stage IB-IIIA NSCLC, saw the longest overall survival in any trial of its kind. These landmark results only further characterize the established survival benefit of adjuvant osimertinib. Read now: jto.org/article/S1556-…

8 year update of ADAURA at #WCLC26 from @DrRoyHerbst - with 3y of adjuvant osimertinib in EGFR mutant NSCLC, 8y OS rate 74% vs 58% with OS HR 0.53 and benefit seen across stages: stage IB HR 0.50, stage II HR 0.60, stage IIIA HR 0.49 - reaffirms standard of care.

keyboard_arrow_left Previous keyboard_arrow_right Next

🔥ADAURA: Adjuvant osimertinib — exploratory 8-year OS landmark update #WCLC2026 🆙 @JTOonline 🎯8-y OS 74% (osimertinib) vs 58% (placebo; HR 0.53); IB-IIIA: 79% vs 64% (HR 0.52) 🎯Ex19del shows stronger OS benefit (HR 0.45) vs L858R (HR 0.72) 🎯Llongest OS follow-up in adjuvant EGFR NSCLC trial 🎙Dr. Yi-Long Wu @ThomasW35874311 @DrRoyHerbst #LCSM @OncoAlert @Larvol @EGFRResisters jto.org/article/S1556-…

Hidehito HORINOUCHI @HHorinouchi

2 weeks ago

🆙#WCLC26 #LCSM Plenary Session 🔥ADAURA: Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: Exploratory 8-Year Overall Survival Landmark Update 🎙️ @DrRoyHerbst 🎯OS HR 0.53 (95%CI 0.38-0.75) 🔢PL03.01 ☑️NCT02511106 🔗

keyboard_arrow_left Previous keyboard_arrow_right Next

0 11 22 7K 2

🆙#WCLC26 #LCSM Plenary Session 🔥ADAURA: Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: Exploratory 8-Year Overall Survival Landmark Update 🎙️ @DrRoyHerbst 🎯OS HR 0.53 (95%CI 0.38-0.75) 🔢PL03.01 ☑️NCT02511106 🔗 vhttps://cattendee.abstractsonline.com/meeting/21487/Session/48 @OncoAlert @Larvol @IASLC @EGFRResisters

keyboard_arrow_left Previous keyboard_arrow_right Next

Hidehito HORINOUCHI @HHorinouchi

a month ago

🆙#WCLC26 #LCSM Plenary Session 🔥ADAURA: Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: Exploratory 8-Year Overall Survival Landmark Update 🎙️ @DrRoyHerbst 🔢PL03.01 ☑️NCT02511106 🔗 cattendee.abstractsonline.com/meeting/21487/… @OncoAlert @Larvol @IASLC @EGFRResisters

0 14 36 8K 9